Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.

von Planting, A. S., van der Burg, M. E., de Boer-Dennert, M., Stoter, G., Verweij, J.
Veröffentlicht 1993

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

von Klijn, J. G., Hoff, A. M., Planting, A. S., Verweij, J., Kok, T., Lamberts, S. W., Portengen, H., Foekens, J. A.
Veröffentlicht 1990

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

von Verweij, J., Herweijer, H., Oosterom, R., van der Burg, M. E., Planting, A. S., Seynaeve, C., Stoter, G., Nooter, K.
Veröffentlicht 1991

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.

von Planting, A. S., van der Burg, M. E., van den Bent, M. J., de Boer-Dennert, M., Stoter, G., Verweij, J.
Veröffentlicht 1996

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

von Pronk, L C, Vasey, P, Sparreboom, A, Reigner, B, Planting, A S Th, Gordon, R J, Osterwalder, B, Verweij, J, Twelves, C
Veröffentlicht 2000

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

von Ma, J., Verweij, J., Planting, A. S., de Boer-Dennert, M., van Ingen, H. E., van der Burg, M. E., Stoter, G., Schellens, J. H.
Veröffentlicht 1995

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.

von Pronk, L. C., Schrijvers, D., Schellens, J. H., de Bruijn, E. A., Planting, A. S., Locci-Tonelli, D., Groult, V., Verweij, J., van Oosterom, A. T.
Veröffentlicht 1998

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

von Schellens, J. H., Ma, J., Planting, A. S., van der Burg, M. E., van Meerten, E., de Boer-Dennert, M., Schmitz, P. I., Stoter, G., Verweij, J.
Veröffentlicht 1996

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.

von Gerrits, C. J., Schellens, J. H., Creemers, G. J., Wissel, P., Planting, A. S., Pritchard, J. F., DePee, S., de Boer-Dennert, M., Harteveld, M., Verweij, J.
Veröffentlicht 1997

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.

von Gerrits, C. J., Creemers, G. J., Schellens, J. H., Wissel, P., Planting, A. S., Kunka, R., Selinger, K., de Boer-Dennert, M., Marijnen, Y., Harteveld, M., Verweij, J.
Veröffentlicht 1996

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off sc...

von Eskens, F A L M, Mom, C H, Planting, A S T, Gietema, J A, Amelsberg, A, Huisman, H, van Doorn, L, Burger, H, Stopfer, P, Verweij, J, de Vries, E G E
Veröffentlicht 2008

A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patie...

von de Wit, R., Kruit, W. H., Lamers, C. H., van 't Veer, M. B., Luyten, A. A., van Beurden, V., Harteveld, M., Planting, A. S., Schmitz, P. I., Stoter, G., Bolhuis, R. L., Verweij, J.
Veröffentlicht 1998

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

von Sparreboom, A, Kehrer, D F S, Mathijssen, R H J, Xie, R, de Jonge, M J A, de Bruijn, P, Planting, A S T, Eskens, F A L M, Verheij, C, de Heus, G, Klaren, A, Zhang, S, Verhaeghe, T, Palmer, P A, Verweij, J
Veröffentlicht 2004